(Total Views: 109)
Posted On: 02/18/2025 5:19:02 PM
Post# of 375
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at 6th Glioblastoma Drug Development Summit
CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the 6th Glioblastoma Drug Development Summit, taking place Feb. 18-20, 2025, in Boston. Chief Medical Officer Dr. Sandra Silberman will present on Feb. 20 at 10:45 a.m. ET, discussing novel formulations of anthracyclines and taxanes designed to cross the blood-brain barrier. The company’s lead candidate, Berubicin, has completed patient enrollment in a pivotal study against glioblastoma, with primary analysis data expected in the first half of 2025. CNS Pharmaceuticals is also advancing TPI 287 and plans to engage with the FDA on trial design. Berubicin has received Fast Track and Orphan Drug Designations from the FDA.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the 6th Glioblastoma Drug Development Summit, taking place Feb. 18-20, 2025, in Boston. Chief Medical Officer Dr. Sandra Silberman will present on Feb. 20 at 10:45 a.m. ET, discussing novel formulations of anthracyclines and taxanes designed to cross the blood-brain barrier. The company’s lead candidate, Berubicin, has completed patient enrollment in a pivotal study against glioblastoma, with primary analysis data expected in the first half of 2025. CNS Pharmaceuticals is also advancing TPI 287 and plans to engage with the FDA on trial design. Berubicin has received Fast Track and Orphan Drug Designations from the FDA.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
